Innocan Pharma Corp

Innocan Pharma Corp

Innocan Pharma Corp was founded with a mission to develop novel drug-delivery technologies for cannabinoids and psychedelics, aiming to treat conditions such as pain, inflammation, and mental health disorders. The company is publicly listed on the Canadian Securities Exchange under the ticker INNO, and its structure is that of a pharmaceutical development firm rather than a family office. The company's strategy has included both research and development of proprietary formulations and the acquisition of intellectual property. It has partnered with institutions such as the Hebrew University of Jerusalem for drug-discovery programs. Its pipeline targets neurological and psychiatric indications, though no products have received regulatory approval as of the latest available data. By 2023, Innocan Pharma had not disclosed a team size or AUM, consistent with its biotech rather than asset-management profile. The company maintains a presence in Canada and Israel, reflecting its research partnerships. It has not disclosed additional offices or adjacent vehicles like a philanthropic foundation. As a publicly traded entity, Innocan Pharma is subject to securities regulation and quarterly reporting, starkly different from the privacy of a family office. Its structure as a single-purpose biotech company with no external capital-allocation function makes it an outlier for the Altss family-office database.